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Abstract
Sleep disorders are problematic for persons with dementia and their family caregivers. This 
randomized controlled trial with crossover evaluated the effects of an innovative blue-white light 
therapy on 17 pairs of home-dwelling persons with dementia and their caregivers. Subjects with 
dementia received blue-white light and control (‘red-yellow’ light) for six weeks separated by a 
four-week washout. Neither actigraphic nor most self-reported sleep measures significantly 
differed for subjects with dementia. For caregivers, both sleep and role strain improved. No 
evidence of retinal light toxicity was observed. Six weeks of modest doses of blue-white light 
appear to improve sleep in caregivers but not in persons with dementia. Greater or prolonged 
circadian stimulation may be needed to determine if light is an effective treatment for persons with 
dementia.
1. Introduction
Sleep disorders are particularly common in persons with Alzheimer’s disease and related 
dementias, leading to adverse effects for individuals and their caregivers. Compared with 
other older adults, persons with dementia demonstrate lower sleep efficiency and more 
frequent arousals, with the severity of the sleep disturbance paralleling the level of 
dementia.1,2 For persons with dementia who live at home, these sleep disorders can be 
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disruptive for family caregivers. Disturbed sleep has been associated with caregiver stress, 
functional decline and depression. Further, disturbed sleep is often given as a reason for 
nursing home placement.2–5
Medications, while frequently prescribed for sleep problems, have low effectiveness6,7 and 
are associated with adverse effects, such as worsening confusion, falls and hip fractures.8–13 
Indeed, a meta-analysis of sedative/hypnotic medications for older people with insomnia 
concluded that ‘in people over 60, the benefits of these drugs may not justify the increased 
risk, particularly if the patient has additional risk factors for cognitive or psychomotor 
adverse events’.14 Valerian root and kava are herbal sleep aids that are sometimes used for 
disturbed sleep. However, their effectiveness has not been established and they too pose 
dangers. Delirium and liver toxicity have been reported with valerian root, and dangerous 
drug interactions have been reported with kava.15 Melatonin appears to be safe and has 
some effect on circadian patterns in adults who do not have dementia; however, four 
randomized trials have failed to demonstrate its effectiveness in dementia patients.16–19 
Thus, an effective, safe alternative to medications would constitute a significant advance in 
the care of persons with dementia who have disturbed sleep.
Bright light therapy is one such alternative that has promise, and its theoretical basis is well-
established. In healthy persons, cyclical changes in light exposure across the 24-hour day 
synchronize a circadian pacemaker in the suprachiasmatic nuclei in the hypothalamus. That, 
in turn, regulates the timing of sleepiness, wakefulness, melatonin and cortisol secretion and 
core body temperature. Impairment of these circadian rhythms is characteristic of persons 
with dementia and contributes to the high prevalence of sleep disturbance.20–23 In addition, 
frail older persons, especially those with dementia, spend increasingly less time outdoors, 
which deprives them of the body’s primary circadian stimulus (CS) – a regular light/dark 
exposure pattern. Therefore, therapies that specifically target delivering a robust diurnal 
light/dark exposure to the circadian system could constitute a physiological method of 
treating many sleep disorders in persons with dementia.
Prior work has shown that exposure to bright white light – at least 2500 lux and as high as 
8000 lux at the cornea – for at least one hour in the morning for a period of at least two 
weeks consolidates the sleep of persons with dementia.24,25 Greater sleep efficiency at night 
has been associated with decreased sleep during daytime hours and, in some cases, reduced 
agitated behaviour.26–34 In other work, light exposure during the day consolidated rest/
activity rhythms in persons with dementia and increased their sleep times at night.35 
Moreover, a five-year, placebo controlled, randomized trial in 189 patients with dementia 
showed that bright light (approximately 1000 lux at the cornea) attenuated cognitive 
deterioration, ameliorated depression symptoms and attenuated the increase in functional 
limitations.36
However, other studies of light therapy for sleep disturbances in persons with dementia have 
failed to yield consistent results, and many of those studies have suffered from 
methodological issues. A 2009 Cochrane review excluded 33 trials for methodological 
reasons and concluded that the five remaining studies failed to demonstrate adequate 
evidence of an impact of light therapy on sleep in persons with dementia.37 As was 
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emphasized by the Cochrane reviewers, the inconsistent research results may be due, in part, 
to methodological problems. These problems include (a) poor tolerance of protocols that 
required persons with dementia to sit for long periods in front of a light box (the most 
commonly used intervention); (b) the use of white light, a nonspecific stimulus that is 
uncomfortably bright, heat-producing and inefficient as a CS (i.e. recent research 
demonstrates that the human circadian system responds more favourably to short 
wavelength (blue) light, with a peak sensitivity close to 460 nanometres (nm))38–41 and (c) 
the use of unselected target populations rather than persons meeting specified thresholds for 
disturbed sleep.37,42
To address these issues, we exposed community-dwelling persons with dementia and 
disturbed sleep to daily (from the time of awakening until 18:00) therapeutic levels of blue-
white lighting in commonly used living areas. The study’s goals were to test the study 
protocol’s ability to identify, recruit and follow through to study completion persons with 
dementia who reside with a family caregiver in a private home or apartment; to test the 
delivery, fidelity, acceptability and safety of the intervention and to gather data on 
outcomes. The use of a light source emitting more short-wavelength radiation allowed for a 
reduction in the light level compared to white light, thereby decreasing glare and power 
consumption. The application of light in commonly used living areas eliminated the 
requirement that persons with dementia sit in front of a light box. The primary hypothesis 
was that lower levels of a blue-white light (300–400 lux at the cornea) would improve sleep 
as measured subjectively and objectively. Outcomes were measured using actigraphy and 
caregiver reports, while fidelity to light exposure was measured directly with a device worn 
by study participants. To address the theoretical possibility of retinal toxicity from blue 




The study was a randomized clinical trial with crossover. All participants received both the 
experimental (blue-white light) and control (red-yellow light) intervention. To determine the 
intervention order, a stratified permuted block randomization scheme was used that 
employed a block size of four participants early in the study and two later in the study, with 
stratification by participant gender.
2.2. Participants
Potential study participants were volunteers recruited from dementia clinics, caregiver 
support groups, senior centres and by posting notices in local newspapers and on university 
email list servers. For persons with dementia, eligibility criteria included a diagnosis of 
dementia documented by a physician (a precise diagnosis was not required, as nonspecific 
diagnoses are common in community populations); residence in a private home or apartment 
with a family caregiver; and having a sleep disturbance as reported by the individual and/or 
family caregiver and verified by a score of 6 or greater on the Pittsburgh Sleep Quality 
Index (PSQI).27 Potential participants were excluded if they scored 26 (females) or 29 
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(males) or higher on the sleep apnea scale of the Sleep Disorders Questionnaire;28 if they 
had a history of severe photosensitivity dermatitis, a progressive retinal disease or a 
permanently dilated pupil; if their primary physician made recommendations against their 
participation (physicians were notified about the study as part of our protocol); or if they 
were identified during a screening eye exam as having moderate or severe macular 
degeneration. Subject dyads were excluded if the caregiver showed evidence of cognitive 
impairment (defined as a score of 24 or less on the Mini-Mental State Examination 
(MMSE))44 or reported a history of severe photosensitivity dermatitis, a permanently 
dilated pupil or moderate or severe macular degeneration.
2.3. Lighting conditions
For the intervention condition, 13,000K (blue-white) compact fluorescent light bulbs 
(Philips Lighting, Eindhoven, NL) were placed in table and floor lamps added to the 
participant’s home in the area where the participant spent most of his/her time. As an 
adjunct, a light-emitting diode (LED) light box (goLITE P2, Philips Respironics, 
Amsterdam, the Netherlands) was placed in the area where the individual ate breakfast and 
lunch. The goLITE P2 is a 6 × 6 inch (15 × 15 cm) device containing an array of 66 LEDs 
with a peak wavelength at approximately 470 nm (full width at half maximum (FWHM) = 
20 nm).
For the control condition, 2700K (yellow-white) compact fluorescent light bulbs (Philips 
Lighting, Eindhoven, NL) were placed in the table and floor lamps and used during the day, 
and a red LED light box was used at breakfast and lunch. The same goLITE device was 
used, but the 470-nm peaking LEDs were replaced with 638-nm peaking LEDs (FWHM = 
15 nm).
The blue-white light source was expected to stimulate the circadian system more than five 
times as much as the yellow-white light source at the same light level (i.e. 400 lux at the 
cornea). The blue LED light box was expected to stimulate the circadian system over one 
thousand times more than the red LED at the same light level (100 lux) at the cornea. These 
circadian-to-visual ratios were calculated using the mathematical model developed by Rea et 
al.45,46
To individualize the placement of floor and table lamps for each participant, the study 
coordinator visited each participant’s home after enrollment, drawing a floor plan, gathering 
light measurements, taking photographs and ascertaining the spaces where the subject spent 
most of the time; this information was then sent to the study’s lighting expert (M.F.), who 
developed a plan designed to provide at least 300–400 lux at the cornea of the participants. 
The floor and table lamps were turned on from the caregiver-reported usual awakening time 
until 18:00, as had been determined to have the most favourable effect on sleep in persons 
with dementia during a previous study.35 The two study conditions were applied for six 
weeks to each participant, with a four-week wash-out period in between.
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The primary outcomes of interest were measures of sleep quality. As a direct measure, wrist 
actigraphy was used among study participants with dementia. Using a wrist-watch-like 
accelerometer (Actiwatch-L®) worn around the wrist, we sought to record actigraphic data 
continuously during the week prior to each condition’s initiation, and during weeks two and 
six of each condition, for a total of six weeks per subject.
Caregiver informants reported subjective sleep quality for both themselves and the person 
with dementia using (a) the PSQI, a 19-item measure that generates one global score and 
seven subscores (the PSQI global index and sleep efficiency score are presented herein);27 
(b) the Medical Outcomes Study (MOS) sleep scale, a 12-item measure that measures 
overall sleep problems and that creates four subscales (sleep disturbance, four items; sleep 
adequacy, two items; day-time somnolence, three items and a sleep problems index, nine 
items)47 and (c) the Epworth Sleepiness Scale, an eight-item scale that rates the likelihood 
of falling asleep during a variety of daytime conditions.48 These data were collected at 
baseline and follow-up of both period one and period two (a total of four times).
Caregivers reported information to assess secondary outcomes, which for subjects with 
dementia included depressive symptoms and quality of life. Depressive symptoms were 
assessed using the Cornell Scale for Depression in Dementia (CSDD)49 and the depression 
instrument (the PHQ-9) from the Patient Health Questionnaire of the PRIME-MD.50,51 The 
CSDD is a 19-item questionnaire that assesses the presence and severity of depressive 
symptoms in individuals with dementia over the previous seven days; scores range from 0 to 
38 and higher scores indicate worse depression.49 The PHQ-9 contains nine items that sum 
to create a score of 0–27, and again, higher scores reflect more depressive symptoms; it 
shows good sensitivity and specificity (88%) in normal adult populations.50,51 Quality of 
life was assessed using a modification of the Quality of Life in Alzheimer’s disease (QOL-
AD) instrument; modified QOL-AD scale scores range from 15 to 60, with higher scores 
indicating better quality of life.52.53
Secondary outcome measures for the family caregiver subjects included the PHQ-950,51 as 
well as measures to assess caregiving hassles and burden. Caregiving hassles were assessed 
using 30 items from three subscales (measuring hassles related to assisting with activities of 
daily living, the subject’s cognitive status and the subject’s behaviour) of the Caregiving 
Hassles Scale (CHS); using these three subscales, CHS scores can range from 0 to 120, with 
higher scores reflecting greater caregiving hassle.54 Caregiving burden was measured using 
the Zarit Burden Interview (ZBI).55,56 The ZBI contains two subscales – one measuring 
psychological distress (termed Personal Strain, comprising 12 items) and the other 
measuring the impact of caregiving (termed Role Strain, comprising six items).57
We also collected information about the subject’s demographic characteristics (e.g. age, 
race/ethnicity and educational level), activities of daily living (ADLs, e.g. independence in 
bathing, dressing and toileting),58 instrumental activities of daily living (IADLs, e.g. ability 
to use the telephone or take medications)59 and cognitive status. To assess cognitive status, 
all subjects completed the MMSE44 and the Saint Louis University Mental Status (SLUMS) 
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examination.60 Like the MMSE, theoretical SLUMS scores range from 0 to 30, and higher 
scores reflect greater cognitive impairment.60
To determine whether and to what extent medication changes may have affected study 
results, we obtained full medication lists at baseline and at the end of study participation 
(four months later) and evaluated them for changes in analgesic, antipsychotic, sedative/
hypnotic and cognitive enhancement medications.
2.5. Protection of human subjects
All study materials and procedures were reviewed and approved by the Biomedical 
Committee of the Institutional Review Board of the University of North Carolina at Chapel 
Hill. Informed consent was obtained from all participants after full explanation of the 
procedures, in accordance with the Helsinki Declaration of 1975.60
2.6. Power
The study’s planned sample size of 18 was selected to provide 80% power, using two-sided 
alpha = 0.05 significance tests, to detect statistically significant differences in the means 
between treatment and control conditions for the amount of night-time sleep (one of the 
primary outcomes) as small as 0.28 hours (17 minutes).
2.7. Fidelity
To evaluate the study’s ability to deliver a CS level of light that differed between the 
intervention and control conditions, each study participant wore a circadian light meter 
pinned to their clothing for three to five days during each of the two study conditions. The 
circadian light meter is a small device that contains two sensors that record and store 
data.61–63 Data from the two photosensor channels were downloaded, and after visually 
inspecting the data and checking the logs provided by caregivers, periods clearly showing 
poor quality data (i.e. device not worn, obviously covered or broken) were removed; if more 
than one-third of a day’s data were removed, that day was not used in the analyses. A total 
of 81 of the 111 files (73%) were used in the analysis.
As a secondary measure of intervention exposure, the research assistant recorded the light 
levels in the location where the intervention was implemented using a standard illuminance 
meter. Additionally, caregiver subjects maintained logs to document time spent outside of 
the home, away from the light intervention and instances of light malfunction.
2.8. Evaluation for potential retinal adverse effects
Because of theoretical concerns about potential retinal effects of blue light (the ‘blue light 
hazard’),43 all participants were evaluated by a retina specialist prior to and at the end of 
study participation. The examination included visual acuity, Amsler Grid evaluation (grid of 
horizontal and vertical lines used to monitor a person’s central visual field) and a dilated eye 
exam. In addition, the study sought to evaluate all participants before and after the study 
period using high-resolution optical coherence tomography (OCT) to assess central retinal 
anatomy and multi-focal electroretinography (mfERG) to assess central retinal function. 
OCT generates a high-resolution (3–5 micron axial resolution) anatomic map of the retinal 
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cell layers of the macula; it requires pupillary dilation and one to two minutes of patient 
cooperation to image each eye. The mfERG measures electrical activity from the central 
retina, primarily the cone photoreceptors and is a high-resolution measure of the central 
retinal function. To obtain the mfERG, a local anaesthetic drop is administered to each eye, 
a contact lens is placed on the cornea, and the study participant must fixate on a target for 
several minutes during the procedure and may not rub the eye for a period afterwards. Due 
to difficulties tolerating the procedures, only 10 participants contributed both baseline and 
follow-up OCT data. MfERG testing was discontinued early in the trial because several 
participants were unable to follow procedure and safety protocols. To address the theoretical 
concern that the blue light hazard is a bigger concern for patients who have had cataract 
surgery (since the native yellow lens acts as a ‘blue blocker’), analyses were conducted for 
the group overall and separately for the eyes that had undergone cataract surgery.
2.9. Analysis
The following summary outcome measures were calculated from the raw actigraphic data: 
total sleep time during the six-hour period after bedtime (for days when bedtime was 
recorded by the caregiver informant) or during the usual sleep time (for days when bedtime 
was not recorded); sleep latency; sleep efficiency during the six-hour sleep analysis period; 
number of sleep bouts (i.e., 1 + (the number of wakefulness episodes recorded by the 
actigraph using a standard algorithm)); inter-daily stability (a measure of the consistency of 
circadian rhythms from day to day) and intra-daily variability (a measure of the difference in 
activity between day and night, i.e. of circadian rhythmicity).29,39
Because the subjective data were collected four times within a crossover design, we were 
able to estimate six effects of interest: the period effect, the effect of the intervention 
compared to the usual light (the lighting at baseline), the effect of the control condition 
compared to the usual light, the carryover for the intervention condition, the carryover for 
the control condition and the intervention condition effect minus the control condition effect, 
which is the effect of primary interest. A linear mixed model was created for each outcome 
with independent variables coded to test for these six fixed effects. A random effect for 
participant was included to account for intra-participant correlation of the outcome. 
Analyses of actigraphic and subjective data were conducted using SAS for Windows 9.1 
software.
Regarding fidelity, illuminance, circadian light (CLA) and CS levels were calculated from 
the circadian light meter data. CLA is a measure of circadian effective light; it is based on 
the model of phototransduction by Rea et al.45,46 The values of CLA are scaled so that 1000 
lux of CIE Illuminant A (incandescent source at 2856 K) is equivalent to 1000 units of CLA. 
CS values are transformed CLA values and correspond to relative melatonin suppression 
after one hour of light exposure for a 2.3-mm diameter pupil during the midpoint of 
melatonin production. Since CS is defined in terms of the circadian system’s input–output 
relationship, including threshold and saturation, it is considered a better measure of the 
circadian effectiveness of light than either lux or CLA.61
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Participants were enrolled between March 2009 and September 2010. Of the 67 participant 
pairs who contacted the project office about the study, 49 (73%) were ineligible. Reasons for 
ineligibility included: absence of a sleep problem, defined as a PSQI score of less than 6 
(33%); living outside the project area (12%); inability to complete the required 
ophthalmologic examination (12%; note that our initial protocol required the study 
participants with dementia to complete the entire ophthalmologic examination; however, this 
requirement was later modified due to the inability of many subjects to complete the mfERG 
component); absence of dementia (10%); participant with dementia not at home during the 
day to receive the intervention (8%); a history of retinal or macular disease (4%); no live-in 
caregiver (5%) or obstructive sleep apnea (2%). An additional 14% of subjects were marked 
as ineligible because their eligibility could not be confirmed; these individuals were largely 
lost to follow-up.
Of the 18 eligible participant pairs, 17 enrolled in the project. One (6%) pair declined 
participation. In terms of subject retention, of the 17 pairs, one completed the first study 
period (in this case, the control period) but not the second (the intervention); another 
completed the first three weeks of the first study period (the intervention period) and then 
discontinued participation. In both cases, the participant with dementia moved to a more 
supportive setting (in one instance, a different daughter’s home, and in another, an assisted 
living community).
Most participants with dementia were over age 80 (65%), female (65%), white (82%), had 
some college education (71%) and represented a wide range of cognitive impairment 
(MMSE mean 12.7, SD 9.1). The caregivers were primarily white (82%), either the 
participant’s spouse (35%) or daughter (47%), not working outside the home (59%) and 
cognitively intact (mean MMSE score = 28.9). Table 1 profiles the care recipients and 
caregivers who participated in the trial.
3.1. Circadian light exposure
Analysis of output from the circadian light meter indicated that for the control condition, the 
median daily CLA was 118, and the median daily CS was 0.145. During the experimental 
condition, the median CLA was 239, and the median CS was 0.230. Therefore, subjects were 
exposed to greater circadian light during the intervention weeks than during the control 
weeks.
3.2. Outcomes for participants with dementia
3.2.1. Actigraphic measures of sleep quality—As shown in Table 2, no significant 
differences in actigraphic sleep measures were noted. The mean sleep latency was 23.3 
minutes under the intervention condition and 24.6 minutes under the control condition. Total 
sleep time (246 vs. 248 minutes) and sleep efficiency (68% vs. 69%) were also similar 
across the two conditions. Computed measures of circadian rhythmicity were not 
significantly different across the two conditions; inter-daily stability averaged 0.41 during 
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both conditions and intra-daily variability averaged 1.21 during the experimental condition 
and 1.20 during the control condition.
3.2.2. Reported sleep quality—For all eight measures of sleep quality reported by 
family caregivers, scores recorded during the intervention condition were better than those 
recorded under the control condition (Table 3). However, the differences were modest, and 
overall, the p-values did not approach statistical significance. The one exception was the 
sleep efficiency subscale of the PSQI, for which the intervention condition was superior to 
usual light (p = 0.045), and the difference between intervention and control, though not 
significant (p = 0.17), trended in the same direction. In addition, the carryover effect for the 
intervention condition was significant (p = 0.026), while the carryover effect for the control 
condition was not (p = 0.52).
3.2.3. Other outcomes—For the IADL scale (Table 3), participants with dementia 
experienced a statistically significant decline in the intervention condition relative to the 
control condition (p = 0.02). For both the CSDD and the PHQ-9, however, the intervention 
condition was associated with a statistically significant improvement compared to usual light 
(p = 0.011 and p = 0.038, respectively), but the contrasts of intervention condition to control 
condition were not significant (p = 0.26 and p = 0.82 respectively). No significant carryover 
effects were observed.
3.3. Outcomes for family caregivers
3.3.1. Reported sleep quality—As shown in Table 4, the effects of intervention 
compared to control conditions were statistically significant for the PSQI Sleep Index (p = 
0.013), the MOS Sleep Adequacy subscale (p = 0.046), the MOS Sleep Problems scale (p = 
0.011) and the MOS Sleep Index (p = 0.012), with all effects representing improved sleep. 
In addition, the intervention condition had significantly better outcomes compared to usual 
light for the MOS Sleep Problems scale (p = 0.009), the MOS Sleep Disturbance subscale (p 
= 0.009) and the MOS Sleep Index (p = 0.023). For the MOS Sleep Disturbance scale, 
carryover for the control condition and global carryover were statistically significant (p = 
0.013 and 0.041, respectively).
3.3.2. Other outcomes—For the Zarit Role Strain subscale, family caregivers 
experienced a statistically significantly improvement during the intervention condition 
relative to usual light (p = 0.037), but not relative to the control condition (p = 0.06). No 
statistically significant effects were found in comparison of intervention to control 
conditions or usual light in terms of caregiver hassles, the Zarit Personal Strain subscale or 
depression scores on the PHQ-9. Neither period nor carryover effects were identified for 
these outcomes.
3.3.3. Ophthalmic effects—No eye-related symptoms were reported by caregivers 
during the control period, whereas a few were reported during the intervention period (i.e. 
eyestrain and eye fatigue during 1% of intervention weeks and glare during 3% of 
intervention weeks). These differences were not statistically significant.
Sloane et al. Page 9













There was no significant change in visual acuity before and after the intervention, nor was 
there change based on the dilated retinal examination. OCT qualitative and quantitative 
measures such as retinal thickness and volume before and after the intervention were 
essentially unchanged. The mean central (subfield = 1 mm) retinal thickness in the right eye 
for nine subjects with both baseline and follow-up data was 273.1 microns (SD 81.5 
microns) at baseline and 274.7 microns (SD 77.5 microns) at follow-up, and the mean 
central subfield thickness in the left eye for 10 subjects with data for both periods was 253.3 
microns (SD 21.1 microns) at baseline and 264.7 microns (SD 49.3 microns) at follow-up. 
None of these differences were statistically significant.
The 15 eyes with prior cataract extraction were evaluated separately; there were no 
significant differences between baseline and follow-up values for visual acuity, central 
subfield thickness or volume (p > 0.47 for all).
3.3.4. Medication use—Of the 17 participants, 10 had no changes in psychotropic or 
cognitive enhancement medications during the study period; 3 had medications discontinued 
(1 each of memantine, eszopiclone and risperidone); 3 had medications added (1 each of 
memantine, escitalopram and risperidone) and 1 had risperidone increased (by 0.125 mg/
day).
4. Discussion
This study sought to determine, on a preliminary basis, whether moderate levels of blue-
white light would improve sleep in community-dwelling persons with dementia and their 
caregivers. The overall hypothesis was that, because the circadian system is maximally 
sensitive to short-wavelength light (peak close to 460 nm), a light source with more short-
wavelength (blue) content would more positively impact objective and subjective sleep 
measures in persons with dementia than light sources commonly used in light therapy 
devices. Our results showed that 300–400 lux of blue-white light at the cornea, delivering a 
median CS value of approximately 0.23, did not significantly change objective and 
subjective sleep parameters in persons with dementia, but did significantly improve the 
subjective sleep of family caregivers. In addition, this level of short-term blue light exposure 
was not associated with any measurable adverse ophthalmic effects, even among persons 
who had undergone cataract surgery.
Most proxy measures of sleep reported by caregivers about the study participants with 
dementia failed to improve (Table 3), and none of the actigraphic measures changed (Table 
2). Some modest evidence suggested that light stimulation levels achieved in the study may 
have had some effect, albeit minor, on sleep patterns. For example, the treatment condition 
was associated with a significant carryover effect (p = 0.026), whereas the control condition 
was not (p = 0.52). Furthermore, medication changes were negligible and therefore would 
not have affected the results. Thus, the overall results suggest that the levels of light 
exposure used in this study were not sufficient to change sleep parameters in subjects with 
dementia. In fact, the robust consistency of the actigraphic measurements is remarkable, 
suggesting that an effective intervention, once found, may have pervasive success. On the 
other hand, secondary outcomes of IADL scores worsened, suggesting that some non-
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circadian effect – such as the progressive deterioration of dementia – may have been present 
and possibly counteracting some of the positive effects of the light treatment. Depression did 
improve, however, possibly indicating that this outcome is more sensitive to the treatment 
and/or at lower levels.
In contrast to the persons with dementia, caregivers showed improvement in multiple 
indicators of sleep quality (Table 4). Both the PSQI Sleep Index and the MOS Sleep Index 
were significantly better during the blue light condition than the red light control condition. 
Furthermore, virtually, all measures of sleep were in a positive direction when treatment 
results were compared with controls. These results suggest that the treatment condition did 
improve sleep in the caregivers, while not having a similar effect on persons with dementia.
The most likely reason for this disparity in results between persons with dementia and their 
caregivers is that the light levels achieved in our study had a more powerful effect on the 
caregivers (who are neurologically normal) than on the persons with dementia (who are not). 
As was revealed by our measurement using the circadian light meter, light-exposure rates 
achieved in the study resulted in a CS value of 0.23, which corresponds to an estimated 23% 
melatonin suppression. This relatively low dose may have been enough to affect normal 
caregivers but not people with dementia, whose neuronal systems are damaged. Also, given 
that we observed a strong carryover effect, it is possible that the circadian systems of 
persons with dementia need more time to respond to the light. In fact, van Someren et al. 
showed that the positive effect of bright light on sleep parameters in persons with dementia 
was only observed after six months of treatment.64 There was no positive effect after six 
weeks of treatment, which was the length of our study. Thus, future work should consider a 
longer treatment period, 24-hour monitoring of light exposure and adequate subjects to 
allow separate analysis of treatment response by dementia severity.
Approximately five million persons in the United States currently suffer from dementia, 
most of whom are cared for at home and that number is anticipated to more than double by 
2050.65 Sleep disturbances affect the majority, which lead to further functional impairment 
and increased risk of placement in nursing homes and residential care/assisted living. Sleep 
disturbances among persons with dementia also have a negative impact on the mental health, 
sleep patterns and physical health of family caregivers. Medications, while widely used, are 
well-recognized as only marginally effective and as having significant side effects. 
Therefore, if light could be administered in a manner that would improve sleep, it would be 
a significant treatment advance. It is recommended that another study with longer exposure 
durations and higher light levels be conducted to determine if a stronger CS can improve 
sleep in this population. Furthermore, the finding of improved sleep among caregivers is 
intriguing and deserves replication, suggesting that with more intensive light levels, perhaps 
both caregiver and care recipient can benefit from such an intervention.
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Table 1
Characteristics of study participants
Characteristic N %
Participants with dementia (N = 17)
Age
  65–79 6 35
  80+ 11 65
Female gender 11 65
White race 14 82
Educational status
  ≤12 years 5 29
  >12 years 12 71
Functional status
  Need assistance in bathing 7 41
  Need assistance in locomotion 4 24
  Need assistance in eating 2 12
  Urinary incontinence 4 24
  Needs assistance in toileting 5 29
  Need assistance in dressing 6 35
Mean SD
Mini-Mental State Examination Score (range, 0–25) 12.7 9.1
St. Louis University Mental Status Score (range, 5–26) 13.8 6.1
Family caregivers (N = 17)
Age
  18–44 3 18
  45–59 7 41
  60+ 7 41
Female gender 13 77
White race 14 82
Educational status
  ≤12 years 4 24
  >12 years 13 77
Relationship to the person with dementia
  Spouse 6 35
  Daughter 8 47
  Daughter-in-law 1 6
  Grandson 2 12
Employment
  Not working for pay 10 59
  Working part-time for pay 2 12
  Working full-time for pay 5 29
Mean SD
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Characteristic N %
Mini-Mental State Examination Score (range 26–30) 28.9 1.5
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